SyB D-0701, is a sustained-release transdermal patch containing granisetron. SyB D-0701 is designed to deliver a commercially available 5HT3-antagonist, through the skin for a continuous period of up to 120 hours, thereby providing the patient with sustained relief from CINV.
We believe that this SyB D-0701 will provide, not only an increase in quality of life, but an improvement in overall patient compliance.
Approximately 70% to 80% of patients experience nausea and vomiting associated with cancer chemotherapy. These symptoms are some of the most painful side effects for patients, and may lead to a host of other complications such as loss of appetite, dehydration, and in severe cases, electrolyte imbalance or nutrient deprivation. Nausea and vomiting aggravate the physical and mental condition of patients, significantly influencing the effectiveness of cancer treatment.
Chemotherapy Induced Nausea and Vomiting is divided into three main categories:
1. Acute
vomiting develops within 24 hours of treatment, usually starting within 1 or 2 hours from initiation of chemotherapy
2. Delayed
vomiting develops from 24 to 48 hours after initiation of chemotherapy, and persists for approximately 120 hours.
3. Anticipatory
vomiting usually develops on the day prior to initiation of chemotherapy.
